Final adult height · people with CAH
1 finding from 1 review
no estimate extracted
26 participants
Very low
QoL · people with CAH
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Androgen normalisation · people with CAH
1 finding from 1 review
no estimate extracted
9 participants
Very low
Persistent bacteriuria · children with lower urinary tract infection
It is very uncertain whether 10‐day cefadroxil changes persistent bacteriuria compared with 10‐day ampicillin (very low certainty).
1 finding from 1 review
Persistent symptoms · children with lower urinary tract infection
It is very uncertain whether 10‐day cefadroxil changes persistent symptoms compared with 10‐day ampicillin (very low certainty).
1 finding from 1 review
Change in MMSE · people with Alzheimer's disease
1 finding from 1 review
Change in capacity for activities of daily living · people with Alzheimer's disease
1 finding from 1 review
Clinician‐rated global impression test (improved compared with baseline assessed using CIBIC‐plus at 24 weeks) · people with Alzheimer's disease
Donepezil 23 mg/day showed no clear difference in clinician‐rated global impression test (improved compared with… compared with donepezil 10 mg/day (moderate certainty).
1 finding from 1 review
Secondary outcome: acceptability of treatment · people with Alzheimer's disease
Donepezil 23 mg/day probably leads to higher acceptability of treatment (as measured by withdrawals from trial… compared with donepezil 10 mg/day (moderate certainty).
1 finding from 1 review
Risk for at least one adverse event per patient · people with Alzheimer's disease
Donepezil 23 mg/day probably leads to higher incidence of adverse events (at least one adverse event by 24 weeks) compared with donepezil 10 mg/day (moderate certainty).
1 finding from 1 review
Change in ADAS‐Cog · people with Alzheimer's disease
1 finding from 1 review
Change in MMSE · people with Alzheimer's disease
1 finding from 1 review
Clinician‐rated global impression test (improved compared with baseline assessed using CIBIC‐plus at 24 weeks) · people with Alzheimer's disease
Donepezil 10 mg/day showed no clear difference in clinician‐rated global impression test (improved compared with… compared with donepezil 5 mg/day (moderate certainty).
1 finding from 1 review
Secondary outcome: acceptability of treatment · people with Alzheimer's disease
Donepezil 10 mg/day probably leads to higher acceptability of treatment (as measured by withdrawals from trial… compared with donepezil 5 mg/day (moderate certainty).
1 finding from 1 review
Risk for at least one adverse event per patient · people with Alzheimer's disease
Donepezil 10 mg/day probably leads to higher incidence of adverse events (at least one adverse event by 24 weeks) compared with donepezil 5 mg/day (moderate certainty).
1 finding from 1 review
Cognitive function · people with Alzheimer's disease
1 finding from 1 review
Persistent bacteriuria · children with lower urinary tract infection
It is very uncertain whether 10‐day trimethoprim changes persistent bacteriuria compared with 10‐day trimethoprim+sulfamethoxazole (very low certainty).
1 finding from 1 review
Persistent symptoms · children with lower urinary tract infection
It is very uncertain whether 10‐day trimethoprim changes persistent symptoms compared with 10‐day trimethoprim+sulfamethoxazole (very low certainty).
1 finding from 1 review
Recurrence · children with lower urinary tract infection
It is very uncertain whether 10‐day trimethoprim changes recurrence compared with 10‐day trimethoprim+sulfamethoxazole (very low certainty).
1 finding from 1 review
Serious adverse events · People with P. vivax malaria1
1 finding from 1 review